Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Patients
with PDAC are often asymptomatic, and many have lymph node and distant metastases as …

Background Standard therapy for advanced endometrial cancer after failure of platinum-based
chemotherapy remains unclear. Methods In this phase 3 trial, we randomly assigned, in a …

Persimmon accumulates a large amount of condensed tannins (proanthocyanidins, PAs) in
the vacuoles of specific cells called ‘tannin cells’ during fruit development. PAs cause …

Background Most patients with ovarian cancer will relapse after receiving frontline platinum-based
chemotherapy and eventually develop platinum-resistant or platinum-refractory …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Simple Summary In this review, we present the latest information on the pathophysiology,
diagnosis, and local and systemic treatment of brain metastases from breast cancer, with a …

Background Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy
and combine the ability of monoclonal antibodies to specifically target tumour cells with …

The purpose of the present study was to identify histological surrogate predictive markers of
pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-…

Next‐generation sequencing ( NGS ) of tumor tissue (ie, clinical sequencing) can guide
clinical management by providing information about actionable gene aberrations that have …

Background Although most patients with epithelial ovarian cancer respond to frontline
platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 JAVELIN …